8-K: NeuroOne Gets Nasdaq Extension for Listing Compliance

NeuroOne Medical Technologies Corporation has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement.

Summary

• NeuroOne Medical Technologies Corporation received a 180-day extension from The Nasdaq Stock Market, LLC until May 4, 2026.
• This extension is to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing.
• The company had previously received an initial notice on May 9, 2025, for failing to meet this requirement for 30 consecutive business days.
• The initial 180-day period to regain compliance ended on November 3, 2025, without the company achieving the required minimum bid price.
• The extension notice has no immediate effect on the company's continued listing status on the Nasdaq Capital Market, which remains fully effective.

Sentiment

Score: 3

Explanation: The company received an extension to avoid immediate delisting, which offers a temporary reprieve. However, the underlying issue of failing to meet the minimum bid price requirement persists, indicating significant challenges in market performance and listing stability, leading to a generally negative sentiment.

Positives

• Nasdaq granted a 180-day extension, providing NeuroOne Medical Technologies Corporation additional time until May 4, 2026, to regain compliance.
• The company's common stock listing on the Nasdaq Capital Market remains fully effective, with no immediate delisting action.

Negatives

• NeuroOne Medical Technologies Corporation failed to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq.
• The company did not regain compliance with the minimum bid price requirement within the initial 180-day period, which concluded on November 3, 2025.

Risks

• Failure to regain compliance with the minimum bid price requirement by May 4, 2026, will result in Nasdaq providing written notification that the company's common stock will be subject to delisting.
• There is no assurance that an appeal to a Nasdaq Hearing Panel, if required, would be successful in preventing delisting.

Future Outlook

NeuroOne Medical Technologies Corporation intends to continue monitoring the closing bid price of its common stock and actively seek to regain compliance with the Minimum Bid Price Requirement within the extended period. If compliance is not achieved by May 4, 2026, the common stock will be subject to delisting, at which point the company may appeal Nasdaq's determination to a Hearing Panel.

Management Comments

• "The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with the Minimum Bid Price Requirement within the Extension Period."
• "The Company... advised Nasdaq of its intent to cure the deficiency within the Extension Period."

Industry Context

This announcement primarily addresses a regulatory compliance issue specific to NeuroOne Medical Technologies Corporation's stock listing, rather than broader industry trends in the medical technology sector. It underscores the ongoing challenges smaller public companies can face in maintaining stock exchange listing requirements, particularly when stock performance is under pressure.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's listing status and the potential risk of delisting, which could impact liquidity and investor confidence.
• Employees may experience indirect impacts on morale and future stability if the company's financial and market position remains precarious.

Next Steps

• NeuroOne Medical Technologies Corporation will continue to monitor the closing bid price of its common stock.
• The company will seek to regain compliance with the Minimum Bid Price Requirement by May 4, 2026.
• If compliance is not regained by the extended deadline, Nasdaq will provide written notification of delisting.
• The company may appeal any delisting determination to a Nasdaq Hearing Panel.

Key Dates

Recommendation

While the Nasdaq extension provides a temporary reprieve from immediate delisting, the fundamental issue of failing to meet the minimum bid price requirement remains unresolved. Investors should hold to observe if the company can successfully regain compliance within the extended period. A 'sell' recommendation would be premature given the granted extension, but a 'buy' is not justified due to the significant delisting risk and the underlying poor stock performance indicated by the non-compliance.

Keywords

NeuroOne Medical Technologies, NMTC, Nasdaq, listing compliance, minimum bid price, delisting risk, SEC 8-K, medical technology, stock market